NKTR - Nektar Therapeutics

-

$undefined

N/A

(N/A)

Nektar Therapeutics NasdaqCM:NKTR Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Location: 455 Mission Bay Boulevard South, San Francisco, CA, 94158, United States | Website: https://www.nektar.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

105.6M

Cash

218.6M

Avg Qtr Burn

-44.22M

Short % of Float

5.81%

Insider Ownership

1.31%

Institutional Own.

67.08%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Rezpegaldesleukin (NKTR-358) Details
Autoimmune disease, Alopecia areata

Phase 2b

Data readout

Rezpegaldesleukin (NKTR-358) Details
Autoimmune disease, Atopic dermatitis

Big Mover™

Susp. Mover™

Phase 2b

Data readout

NKTR-255 + Avelumab Details
Urothelial carcinoma, Cancer

Phase 2

Data readout

NKTR-255 Details
Cancer, B-cell lymphoma

Phase 2

Update

NKTR-255 (IL-15R agonist) + Cetuximab (Erbitux) (EGFR inhibitor) Details
Colorectal cancer , Head and neck cancer, Head and neck squamous cell carcinoma, Cancer

Phase 1/2

Update

NKTR-255 (IL-15 agonist) +/- Daratumumab Details
Non-Hodgkin lymphoma, Multiple myeloma, Cancer

Phase 1/2

Update

NKTR-255 (IL-15 agonist) + C-TIL051 Details
Cancer, Non-small cell lung carcinoma

Phase 1

Data readout

NKTR-0165 Details
Inflammatory disease

IND

Submission

NKTR-358 Details
Autoimmune disease, Ulcerative colitis

Failed

Discontinued

Failed

Discontinued

Dapirolizumab Pegol (anti-CD40L) Details
Systemic lupus erythematosus, Autoimmune disease

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

Bempegaldesleukin (NKTR-214)+ OPDIVO (Nivolumab) Details
Urothelial cancer, Cancer, Bladder cancer

Failed

Discontinued

Failed

Discontinued

Onzeald (etirinotecan pegol) Details
Metastatic breast cancer to brain, Cancer

Failed

Discontinued

Failed

Discontinued

Bempegaldesleukin (NK-214) + VB10.NEO Details
Head and neck squamous cell carcinoma, Cancer

Failed

Discontinued

Rezpegaldesleukin (LY3471851) (NKTR-358) Details
Autoimmune disease, Systemic lupus erythematosus

Failed

Discontinued

Failed

Discontinued